Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Michael Scheurlen

Showing results (11-20 of 40) with videos related to

Pageof 4
Sort By:
Acta Dermato-Venereologica|April 13, 2018
Structured Diagnostic Approach and Risk Assessment in Mucous Membrane Pemphigoid with Oesophageal InvolvementSandrine Benoit, Michael Scheurlen, Matthias Goebeler, et al.
Oncology|June 20, 2018
Use of Gene Expression Analysis for Discrimination of Primary and Secondary Adenocarcinoma of the LiverHolger G Hass, Ulrich Vogel, Michael Scheurlen, et al.
Gut and Liver|December 23, 2017
Subclassification and Detection of New Markers for the Discrimination of Primary Liver Tumors by Gene Expression Analysis Using Oligonucleotide ArraysHolger G Hass, Ulrich Vogel, Michael Scheurlen, et al.
World Journal of Gastroenterology|March 29, 2005
Psychiatric side effects of pegylated interferon alfa-2b as compared to conventional interferon alfa-2b in patients with chronic hepatitis CMichael-R Kraus, Arne Schäfer, Herbert Csef, et al.
European Journal of Gastroenterology & Hepatology|November 18, 2005
Physician-patient relationship and disclosure behaviour in chronic hepatitis C in a group of German outpatientsArne Schäfer, Michael Scheurlen, Marc Felten, et al.
Anticancer Research|November 1, 2016
Gene-expression Analysis Identifies Specific Patterns of Dysregulated Molecular Pathways and Genetic Subgroups of Human Hepatocellular CarcinomaHolger G Hass, Ulrich Vogel, Michael Scheurlen, et al.
Oncology Research and Treatment|December 23, 2014
Overexpression of tumor-associated trypsin inhibitor (SPINK1/TATI) in hepatitis C-associated hepatocellular carcinoma: potential implications for viral hepatocarcinogenesisHolger G Hass, Jürgen Jobst, Ulrich Vogel, et al.
Chemotherapy|May 15, 2007
Sustained virological response in the antiviral therapy of chronic hepatitis C: is there a predictive value of interferon-induced depression?Arne Schäfer, Michael Scheurlen, Benedikt Weissbrich, et al.
Clinical Pharmacology and Therapeutics|January 8, 2005
Neurocognitive changes in patients with hepatitis C receiving interferon alfa-2b and ribavirinMichael R Kraus, Arne Schäfer, Saskia Wissmann, et al.
The Journal of Clinical Psychiatry|June 26, 2003
Psychiatric symptoms in patients with chronic hepatitis C receiving interferon alfa-2b therapyMichael R Kraus, Arne Schäfer, Hermann Faller, et al.
Pageof 4

Showing results (11-20 of 40) with videos related to

Sort By:
Pageof 4
Acta Dermato-Venereologica|April 13, 2018
Structured Diagnostic Approach and Risk Assessment in Mucous Membrane Pemphigoid with Oesophageal InvolvementSandrine Benoit, Michael Scheurlen, Matthias Goebeler, et al.
Oncology|June 20, 2018
Use of Gene Expression Analysis for Discrimination of Primary and Secondary Adenocarcinoma of the LiverHolger G Hass, Ulrich Vogel, Michael Scheurlen, et al.
Gut and Liver|December 23, 2017
Subclassification and Detection of New Markers for the Discrimination of Primary Liver Tumors by Gene Expression Analysis Using Oligonucleotide ArraysHolger G Hass, Ulrich Vogel, Michael Scheurlen, et al.
World Journal of Gastroenterology|March 29, 2005
Psychiatric side effects of pegylated interferon alfa-2b as compared to conventional interferon alfa-2b in patients with chronic hepatitis CMichael-R Kraus, Arne Schäfer, Herbert Csef, et al.
European Journal of Gastroenterology & Hepatology|November 18, 2005
Physician-patient relationship and disclosure behaviour in chronic hepatitis C in a group of German outpatientsArne Schäfer, Michael Scheurlen, Marc Felten, et al.
Anticancer Research|November 1, 2016
Gene-expression Analysis Identifies Specific Patterns of Dysregulated Molecular Pathways and Genetic Subgroups of Human Hepatocellular CarcinomaHolger G Hass, Ulrich Vogel, Michael Scheurlen, et al.
Oncology Research and Treatment|December 23, 2014
Overexpression of tumor-associated trypsin inhibitor (SPINK1/TATI) in hepatitis C-associated hepatocellular carcinoma: potential implications for viral hepatocarcinogenesisHolger G Hass, Jürgen Jobst, Ulrich Vogel, et al.
Chemotherapy|May 15, 2007
Sustained virological response in the antiviral therapy of chronic hepatitis C: is there a predictive value of interferon-induced depression?Arne Schäfer, Michael Scheurlen, Benedikt Weissbrich, et al.
Clinical Pharmacology and Therapeutics|January 8, 2005
Neurocognitive changes in patients with hepatitis C receiving interferon alfa-2b and ribavirinMichael R Kraus, Arne Schäfer, Saskia Wissmann, et al.
The Journal of Clinical Psychiatry|June 26, 2003
Psychiatric symptoms in patients with chronic hepatitis C receiving interferon alfa-2b therapyMichael R Kraus, Arne Schäfer, Hermann Faller, et al.
Pageof 4